John H. Burbank III Portfolio
Invests via Passport Capital LLC | Managed by John H. Burbank III
Invests via Passport Capital LLC
Managed by John H. Burbank III
Automatically Tracked
Chicago-based asset manager and founder with multi-decade experience in public and private markets, concentrating on value-oriented and event-driven strategies and macro portfolio construction. John H. Burbank III built firms that combine concentrated equity positions with operational engagement and board-level oversight, and frequently allocates to special situations and distressed opportunities. Active in capital formation, he maintains a track record of cross-asset allocation and philanthropic board service.
Chicago-based asset manager and founder with multi-decade experience in public and private markets, concentrating on value-oriented and event-driven strategies and macro portfolio construction. John H. Burbank III built firms that combine concentrated equity positions with operational engagement and board-level oversight, and frequently allocates to special situations and distressed opportunities. Active in capital formation, he maintains a track record of cross-asset allocation and philanthropic board service.
Investment Philosophy & Strategy
Combines value-driven, event-oriented investing with disciplined macro portfolio construction, favoring concentrated, high‑conviction equity positions and special-situations exposure. Seeks mispriced assets across public and private markets where operational engagement or board-level oversight can unlock value. Allocates opportunistically to distressed and catalyst‑led opportunities, balancing long-term fundamental conviction with tactical hedges and cross‑asset diversification to manage downside and compound capital over multi-year horizons.
Combines value-driven, event-oriented investing with disciplined macro portfolio construction, favoring concentrated, high‑conviction equity positions and special-situations exposure. Seeks mispriced assets across public and private markets where operational engagement or board-level oversight can unlock value. Allocates opportunistically to distressed and catalyst‑led opportunities, balancing long-term fundamental conviction with tactical hedges and cross‑asset diversification to manage downside and compound capital over multi-year horizons.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
136.34%
Gain +0.77%
Monthly
2.99%
Yearly
42.43%
Drawdown
52.02%
$18.49B
Equity
Holdings
$18.49B
Investment
$12.45B
$30.3B
Profit +$105.42M
Realized
$24.23B
Unrealized
$6.07B
Dividends
$50.37M
Goals
Avg. 95.75% completed goals
Yearly
Gain > 8% 2026
Yearly
Loss < $300M 2026
Yearly
Loss < 20% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0.77%
Profit
$105.42M
Win %
76%
This Week
Compared To Last Week
Gain
1.49%
Profit
$272.07M
Win %
76%
This Month
Compared to last month
Gain
6.22%
Profit
$1.08B
Win %
76%
This Year
Compared to last year
Gain
6.64%
Profit
$1.15B
Win %
73%
SGMT Sagimet Biosciences Inc.
+13.69%
+$1.21M 
FTH Faeth Therapeutics, Inc.
+13.28%
+$4.88M 
LBRX LB Pharmaceuticals Inc.
+7.92%
+$701,000 
AVLN Avalyn Pharma Inc.
+7.3%
+$934,500 
EIKN Eikon Therapeutics, Inc.
+6.97%
+$399,999.6 
CELC Celcuity Inc.
+6.24%
+$42.75M 
DNTH Dianthus Therapeutics Inc.
+5.8%
+$5.42M 
CERS Cerus Corporation
+5.28%
+$959,314.65 
AKTS Akoustis Technologies Inc.
+4.79%
+$1.14M 
EVMN Evommune, Inc.
+4.12%
+$491,486.2 
GENB Generate Biomedicines, Inc.
+4.06%
+$868,397.22 
WVE Wave Life Sciences Ltd.
+4.04%
+$172,753.98 
PBLS Parabilis Medicines, Inc.
+3.92%
+$700,000 
ABCL AbCellera Biologics Inc.
+3.78%
+$13.7M 
JBIO Jade Biosciences Inc.
+3.78%
+$1.11M 
ALMS Alumis Inc.
+3.69%
+$1.81M 
PRLD Prelude Therapeutics Incorporated
+3.54%
+$1.92M 
KOD Kodiak Sciences Inc.
+3.43%
+$27.29M 
DSGN Design Therapeutics, Inc.
+3.06%
+$1.18M 
IMNM Immunome Inc.
+2.95%
+$43,138.68 
TECX Tectonic Therapeutic Inc.
+2.74%
+$565,242.84 
KYMR Kymera Therapeutics Inc.
+2.6%
+$25.71M 
IONS Ionis Pharmaceuticals, Inc.
+2.45%
+$2.81M 
EWTX Edgewise Therapeutics, Inc.
+2.29%
+$3.66M 
RCUS Arcus Biosciences Inc.
+2.15%
+$523,785.92 
MIRM Mirum Pharmaceuticals Inc.
+1.89%
+$833,973.25 
ALGS Aligos Therapeutics Inc.
+1.77%
+$9,966.6 
XNCR Xencor Inc.
+1.52%
+$385,737.1 
MPLT MapLight Therapeutics, Inc.
+1.47%
+$61,999.85 
NGNE Neurogene Inc.
+1.43%
+$505,762.41 
ELVN Enliven Therapeutics, Inc.
+1.31%
+$687,944.25 
ARWR Arrowhead Pharmaceuticals Inc.
+1.23%
+$2.09M 
TYRA Tyra Biosciences, Inc.
+1.08%
+$2,863.89 
BNTX BioNTech SE
+1.05%
+$116,150.23 
CYTK Cytokinetics, Incorporated
+0.93%
+$143,661.56 
TCRX TScan Therapeutics Inc.
+0.91%
+$19,493.46 
RVMD Revolution Medicines Inc.
+0.85%
+$19.57M 
TARA Protara Therapeutics Inc.
+0.76%
+$29,148.42 
AVTX Avalo Therapeutics Inc.
+0.72%
+$77,000 
NTLA Intellia Therapeutics Inc.
+0.68%
+$74,418.56 
VRDN Viridian Therapeutics Inc.
+0.41%
+$214,472.25 
CRNX Crinetics Pharmaceuticals Inc.
+0.31%
+$611,380.9 
CTMX CytomX Therapeutics Inc.
+0.3%
+$49,758.26 
TRDA Entrada Therapeutics Inc.
+0.13%
+$50,727.3 
RAPP Rapport Therapeutics Inc.
+0.13%
+$92,825.4 
MDGL Madrigal Pharmaceuticals, Inc.
+0.04%
+$407,194.89 
BEIGF BeiGene Ltd.
0%
$0 
IMVT Immunovant Inc.
0%
$0 1510
15102KAA8
0%
$0 
SRZNW Surrozen Inc.
-38.71%
-$2,000 
SKYE Skye Bioscience Inc.
-7.21%
-$61,434.54 
SMMT Summit Therapeutics Inc.
-4.64%
-$21.31M 
SANA Sana Biotechnology, Inc.
-3.27%
-$37,257.96 
XENE Xenon Pharmaceuticals Inc.
-2.93%
-$695,991.04 
ABSI Absci Corporation
-2.91%
-$587,070.82 
SERA Sera Prognostics Inc.
-2.49%
-$274,908.5 
VTVT vTv Therapeutics Inc.
-2.37%
-$108,269.22 
GLUE Monte Rosa Therapeutics, Inc.
-2.15%
-$1.48M 
INSM Insmed Inc.
-2.05%
-$22.78M 
BCYC Bicycle Therapeutics plc American Depositary Receipt
-2.01%
-$870,828.56 
DNLI Denali Therapeutics Inc.
-1.69%
-$1.57M 
IMTX Immatics N.V.
-1.56%
-$1.43M 
CLDX Celldex Therapeutics Inc.
-1.55%
-$780,523.26 
IRON Disc Medicine Inc.
-1.46%
-$409,099.39 
KNSA Kiniksa Pharmaceuticals International, plc
-1.39%
-$3.06M 
REPL Replimune Group Inc.
-1.38%
-$2.32M 
VSTM Verastem Inc.
-1.35%
-$224,940.42 
SION Sionna Therapeutics Inc.
-1.22%
-$32,000 
IDYA Ideaya Biosciences Inc.
-1.04%
-$1.9M 
DYN Dyne Therapeutics Inc.
-1%
-$211,496.74 
ALKS Alkermes plc
-0.79%
-$3.9M 
TSHA Taysha Gene Therapies Inc.
-0.67%
-$160,190.24 
GRAL Grail, Inc.
-0.54%
-$1.49M 
NRIX Nurix Therapeutics Inc.
-0.52%
-$652,202.5 
RYTM Rhythm Pharmaceuticals Inc.
-0.47%
-$3.03M 
ACAD Acadia Pharmaceuticals Inc.
-0.46%
-$5.58M 
PRAX Praxis Precision Medicines Inc.
-0.45%
-$2.89M 
RLAY Relay Therapeutics Inc.
-0.35%
-$197,874.81 
GPCR Structure Therapeutics Inc.
-0.35%
-$272,180.51 
INCY Incyte Corporation
-0.29%
-$10.77M 
ROIV Roivant Sciences Ltd
-0.22%
-$377,346.48 
TNGX Tango Therapeutics Inc.
-0.2%
-$16,666.65 
STOK Stoke Therapeutics Inc.
-0.13%
-$133,467.88 
DBVT Dbv Technologies S.A. Sponsored ADR
-0.07%
-$14,614.25 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 3681 | Longs Won 1929/3681 52% | Profit Factor 4.51 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $79.73M |
| Average Win $20.18M | Best Trade (Sep 30) $2.4B | Sharpe Ratio -23.75 |
| Average Loss -$4.92M | Worst Trade (Aug 15) -$807.89M | Z-Score -3.53 (100%) |
| Commissions $0 | Avg. Trade Length 2y 2m 1w 3d | Expectancy $8.23M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.65% |
| Consecutive Losing Trades | 3,759 | 3,383 | 3,008 | 2,632 | 2,256 | 1,880 | 1,504 | 1,128 | 752 | 376 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 1510 15102KAA8 | 30.75M | $40.91M | $40.91M | - | - | - | 0.0 |
| ABCL AbCellera Biologics Inc. | 33.01M | $543.36M | $375.84M | - | -$167.52M | -30.83% | +3.783% |
| ABSI Absci Corporation | 2.13M | $7.45M | $19.61M | - | $12.16M | 163.18% | -2.907% |
| ACAD Acadia Pharmaceuticals Inc. | 42.91M | $676.97M | $1.21B | - | $535.32M | 79.08% | -0.458% |
| AKTS Akoustis Technologies Inc. | 996,351 | $17.82M | $24.84M | - | $7.01M | 39.35% | +4.792% |
| ALGS Aligos Therapeutics Inc. | 83,055 | $719,256 | $572,248.95 | - | -$147,007.05 | -20.44% | +1.773% |
| ALKS Alkermes plc | 10.01M | $270.05M | $491.2M | - | $221.15M | 81.89% | -0.789% |
| ALMS Alumis Inc. | 2.01M | $30.69M | $50.94M | - | $20.24M | 65.94% | +3.687% |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.99M | $70.7M | $172.65M | - | $101.95M | 144.2% | +1.227% |
| AVLN Avalyn Pharma Inc. | 350,000 | $10.14M | $13.74M | - | $3.59M | 35.44% | +7.299% |
| AVTX Avalo Therapeutics Inc. | 550,000 | $10.16M | $10.77M | - | $610,500 | 6.01% | +0.72% |
| BCYC Bicycle Therapeutics plc American Depositary Receipt | 10.89M | $226.24M | $42.45M | - | -$183.79M | -81.24% | -2.01% |
| BEIGF BeiGene Ltd. | 8.8M | $1.57B | $193.16M | - | -$1.38B | -87.71% | 0.0 |
| BNTX BioNTech SE | 119,743 | $12.75M | $11.15M | - | -$1.6M | -12.57% | +1.053% |
| CELC Celcuity Inc. | 7.92M | $196.34M | $728.25M | - | $531.91M | 270.92% | +6.236% |
| CERS Cerus Corporation | 6.4M | $22.12M | $19.12M | - | -$3M | -13.56% | +5.282% |
| CLDX Celldex Therapeutics Inc. | 1.18M | $37.57M | $49.61M | - | $12.04M | 32.05% | -1.549% |
| CRNX Crinetics Pharmaceuticals Inc. | 2.35M | $97.29M | $199.17M | - | $101.88M | 104.71% | +0.308% |
| CTMX CytomX Therapeutics Inc. | 4.98M | $13.76M | $16.72M | - | $2.96M | 21.48% | +0.299% |
| CYTK Cytokinetics, Incorporated | 211,267 | $18M | $15.66M | - | -$2.34M | -12.98% | +0.926% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for John H. Burbank III?
The largest contributions to the portfolio's profits come from the following stocks: SGEN - $10.15B, 45337CAH5 - $3.03B, PCYC - $2.4B, VPHM - $1.59B, and 795435AC0 - $1.58B. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Dbv Technologies S.A. Sponsored ADR - $294.57M, SUPG - $229.13M, Invitae Corp - $211.7M, Heron Therapeutics Inc - $145.04M, and TRMS - $142.57M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does John H. Burbank III's portfolio generate?
The portfolio generates substantial dividend income, with a total of $50.37M earned over time. The largest contributors to dividend income include AbbVie Inc - $48.49M, Spectrum Pharmaceuticals Inc - $498,054, Gilead Sciences Inc - $429,991.4, Biogen Inc - $366,795, and Ligand Pharmaceuticals Inc - $357,679.55. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are John H. Burbank III's monthly returns?
John H. Burbank III's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can John H. Burbank III's strategy be considered aggressive or moderate?
John H. Burbank III's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow John H. Burbank III's strategy?
John H. Burbank III's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
